ArticleMethods in molecular biology (Clifton, N.J.)2011
Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.
Article in Methods in molecular biology (Clifton, N.J.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent.NMR in biomedicine · 2017Article
- Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.Bioconjugate chemistry · 2016Article
- Heteropentanuclear Oxalato-Bridged nd-4f (n=4, 5) Metal Complexes with NO Ligand: Synthesis, Crystal Structures, Aqueous Stability and Antiproliferative Activity.Chemistry (Weinheim an der Bergstrasse, Germany) · 2015Article
- A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas.Molecular imaging and biology · 2015Article
- Synthesis and bioactivity of MSH4 oligomers prepared by an ATetrahedron letters · 2015Article
- Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells.Chembiochem : a European journal of chemical biology · 2014Article
- Sensing lanthanide metal content in biological tissues with magnetic resonance spectroscopy.Sensors (Basel, Switzerland) · 2013Article
- A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma.Nanomedicine (London, England) · 2012Article
- Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.Bioconjugate chemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The use of fluorescent (or luminescent) and metal contrast agents in high-throughput screens, in vitro assays, and molecular imaging procedures has rapidly expanded in recent years. Here we describe the development and utility of high-affinity ligands for cancer theranostics and other in vitro screening -studies. In this context, we also illustrate the syntheses and use of heteromultivalent ligands as targeted imaging agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.